Park K, Kim JS, Kim JH, Kim YC, et al. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer 2021;21:802.
PMID: 34253172